To view this email as a web page, click here.
Dr. Bartt Scott discusses safety, adverse event management, and dose modifications
A Treatment Option for Patients with Myelofibrosis
 
Thursday, December 16, 2021 • 7:00pm - 8:00pm ET
 
TOPICS OF DISCUSSION AT THIS VIRTUAL EVENT INCLUDE:
  • Clinical data supporting a treatment option for patients with intermediate-2 or high-risk myelofibrosis
  • NCCN Clinical Practice Guidelines surrounding use of a treatment option in myelofibrosis
  • Safety, adverse event management, and dose modifications
  • Steps for starting your patients on this treatment option
 
 
 
Expert insights provided by:
 

Bart Scott, MD

Professor, Transplantation Program
Clinical Research Division, Fred Hutch

 
 

Pursuant to the PhRMA Code on Interactions with Healthcare Professionals, attendance at this webcast program is restricted to U.S. healthcare professionals.

Bristol Myers Squibb will report transfers of value made to U.S.healthcare professionals to the extent required by federal and state laws, as applicable. To learn more about how Bristol Myers Squibb complies with the U.S. Physician Payments Sunshine Act visit https://www.bms.com/about-us/responsibility/position-on-key-issues/transparency/global-interactions-with-healthcare-professionals.html

This is a promotional program and no CME credits are offered.

Intended for specific recipient only, please do not forward or further disseminate.
© 2021 Bristol-Myers Squibb Company.
HE-US-2100140    11/21

Learn more about MJH Live Sciences products, partnerships, and solutions by visiting our website at https://www.mjhlifesciences.com/
 
OncLive® – an MJH Life Sciences™ brand
2 Clarke Drive Suite 100
Cranbury, NJ, 08512 United States

Privacy Policy

Update Profile      Manage Subscriptions      Unsubscribe